Publications by authors named "P Jenkin"
Article Synopsis
- Older individuals with frailty or cognitive impairment are at greater risk for severe illness from COVID-19, prompting the creation of specialized clinical guidelines to manage their care effectively.
- A panel of experts established two clinical flow charts to guide healthcare providers in the management of these populations, emphasizing care goals, communication, medication management, and symptom relief.
- Recent guidelines aim to enhance clinical practice by focusing on quality care for older adults, addressing the unique challenges faced by those with COVID-19 who are also in need of palliative care.*
Article Synopsis
- - Refractory acute graft-versus-host disease (R-aGvHD) is a major complication after stem cell transplants, often leading to high mortality due to both the disease and treatment-related infections, though mesenchymal stromal cells (MSC) show potential as a remedy.
- - A unique MSC product, MSC-FFM, created from pooled bone marrow cells from multiple donors, has been used clinically in Germany and has shown promising initial results regarding its immunosuppressive capacity and safety.
- - In a follow-up study involving 92 patients treated with MSC-FFM, there was an 82% response rate, a 64% overall survival rate after six months, and very low mortality due to
Background: Medication management of type 2 diabetes mellitus (T2DM) in residential aged care facilities (RACFs) requires consideration of the residents’ goals of care and susceptibility to adverse drug events (ADEs).
Objective: The aim of this article is to review best practice medication management for residents diagnosed with T2DM.
Discussion: Management of T2DM in RACFs is often focused on maintaining residents’ quality of life rather than intensive glycaemic management to reduce chronic complications, because the risks of intensive glycaemic management typically outweigh the potential benefits.
Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of alterations in transcription factors, epigenetic regulators and signaling molecules. To determine how different mutant regulators establish AML subtype-specific transcriptional networks, we performed a comprehensive global analysis of cis-regulatory element activity and interaction, transcription factor occupancy and gene expression patterns in purified leukemic blast cells. Here, we focused on specific subgroups of subjects carrying mutations in genes encoding transcription factors (RUNX1, CEBPα), signaling molecules (FTL3-ITD, RAS) and the nuclear protein NPM1).
View Article and Find Full Text PDFThe inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes of patients with aGvHD receiving MSC products. We developed a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses, referred to as "MSC-Frankfurt am Main (MSC-FFM)". Herein, we report outcomes of the 69 patients who have received MSC-FFM.
View Article and Find Full Text PDF